Bluebird’s Improved Vector Yields Promising Early Phase II Data In Beta Thalassemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Two patients achieve independence from transfusions and show normalizing levels of hemoglobin in Phase II trial of experimental viral vector-based gene therapy. Bluebird’s share price soared on the promising news.